this collaboration agreement is currently focused on the discovery of new therapeutics for ophthalmic indications and originally provided for a three-year research term , which has been extended by the parties through march 2013. our two other collaboration agreements with allergan involve the development of product candidates in the areas of 39 chronic pain and glaucoma . we are eligible to receive payments upon achievement of development and regulatory milestones , as well as royalties on future product sales , if any , under each of our three collaboration agreements with allergan . each of our agreements with allergan is subject to early termination upon specified events , including , in the case of one of our agreements , if we have a change in control . upon the conclusion of the research term under each agreement , allergan may terminate the agreement by notice . in march 2009 , we entered into a collaboration agreement with meiji seika pharma . under the agreement , we are eligible to receive up to $ 25 million in aggregate payments , consisting of $ 3 million in license fees and up to $ 22 million in payments upon achievement of development and regulatory milestones in the licensed asian territory . in addition , we are eligible to receive royalties on future product sales , if any , in the asian territory . meiji seika pharma also is responsible for the first $ 15 million of designated development expenses and we will share the remaining expenses through clinical proof-of-concept , subject to possible adjustment in the event we further license the program outside of the asian territory . as of december 31 , 2011 , we had received an aggregate of $ 4.3 million in payments from meiji seika pharma , consisting of license fees and reimbursed research and development expenses . our agreement with meiji seika pharma is subject to early termination upon specified events . in may 2009 , we entered into a collaboration agreement with biovail , pursuant to which we received a non-refundable $ 30 million upfront payment . under this collaboration , we also were eligible to receive potential development , regulatory and sales milestones as well as royalties on future net sales of pimavanserin . in october 2010 , we entered an agreement with biovail to regain all rights to pimavanserin and conclude our collaboration . in connection with this agreement , we recorded all remaining revenues related to our collaboration biovail , which totaled $ 34.7 million during the fourth quarter of 2010. we recognized aggregate revenues relating to the biovail collaboration of $ 39.5 million during the year ended december 31 , 2010. we have no future obligations to biovail . research and development expenses our research and development expenses have consisted primarily of fees paid to external service providers , salaries and related personnel expenses , facilities and equipment expenses , and other costs . we charge all research and development expenses to operations as incurred . our research and development activities are primarily focused on our most advanced product candidates , including pimavanserin . we currently are responsible for all costs incurred in the development of pimavanserin as well as for the costs associated with our other internal programs . pursuant to our collaboration , meiji seika pharma is responsible for the first $ 15 million of designated development expenses for the product candidate , am-831 , and we and meiji seika pharma will share remaining expenses through clinical proof-of-concept , subject to possible adjustment . as of december 31 , 2011 , approximately $ 2.8 million of the designated development expenses had been incurred . we expect to coordinate a significant portion of the planned external development services and , accordingly , we may incur the related development costs for these external services and receive reimbursement of meiji seika pharma 's portion of these costs pursuant to the agreement . meiji seika pharma is responsible for all costs associated with the development of am-831 in the asian territory . we are not responsible for , nor have we incurred , development expenses in our clinical programs for chronic pain and glaucoma , which we are pursuing in collaboration with allergan . 40 we use external service providers to manufacture our product candidates to be used in clinical trials and for the majority of the services performed in connection with the preclinical and clinical development of our product candidates . we have used our internal research and development resources , including our employees and discovery infrastructure , across several projects and many of our costs have not been attributable to a specific project but were directed to broadly applicable research activities . accordingly , we have not reported our internal research and development costs on a project basis . to the extent that external expenses are not attributable to a specific project , they are included in other external costs . the following table summarizes our research and development expenses for the years ended december 31 , 2011 , 2010 , and 2009 ( in thousands ) : replace_table_token_4_th at this time , due to the risks inherent in the clinical trial process and given the stage of development of our programs , we are unable to estimate with any certainty the costs we will incur for the continued development of our product candidates for potential commercialization . due to these same factors , we are unable to determine the anticipated completion dates for our current research and development programs . clinical development timelines , probability of success , and development costs vary widely . story_separator_special_tag the decrease in internal research and development costs was primarily attributable to $ 4.3 million in decreased salaries and related personnel costs , and decreases in laboratory supply , equipment , facility and other costs resulting from a restructuring and related workforce reductions implemented in october 2009. salaries and related personnel costs for the year ended december 31 , 2009 included a charge of $ 905,000 in connection with these workforce reductions . general and administrative expenses general and administrative expenses decreased to $ 6.5 million in 2010 , including $ 984,000 in stock-based compensation , from $ 10.3 million in 2009 , including $ 1.3 million in stock-based compensation . the decrease in general and administrative expenses was primarily due to $ 2.3 million in decreased salaries , related personnel costs and other costs resulting from our october 2009 restructuring and $ 1.6 million in decreased external service costs . story_separator_special_tag operating assets and liabilities , including changes in deferred revenue , accounts payable and accrued expenses , and a non-cash charge resulting from termination of our swedish facility lease during 2011. deferred revenue decreased by $ 57,000 in 2011 compared to a decrease of $ 25.3 million in 2010. the decrease in deferred revenue in 2010 was primarily attributable to the conclusion of our collaboration with biovail in october 2010 and the recognition of all remaining revenue under this collaboration . accounts payable and accrued expenses increased by an aggregate of $ 248,000 in 2011 compared to an aggregate decrease of $ 3.1 million in 2010. our accounts payable and accrued expenses fluctuated significantly during these years primarily due to the timing of payments made and expenses incurred for external service costs related to our clinical trials . 45 the decrease in net cash used in operating activities in 2010 relative to 2009 was primarily due to net income of $ 15.1 million in 2010 compared to a net loss of $ 45.1 million in 2009 , as well as changes in operating assets and liabilities , including changes in deferred revenue , and accounts payable and accrued expenses . deferred revenue decreased by $ 25.3 million in 2010 compared to an increase in deferred revenue of $ 28.2 million in 2009. the decrease in deferred revenue in 2010 was primarily attributable to the recognition of $ 25.9 million in deferred revenue in connection with the conclusion of our collaboration with biovail in october 2010. the increase in deferred revenue in 2009 was primarily attributable to the $ 30 million non-refundable upfront payment received pursuant to our collaboration with biovail as well as initial licensing fees received from our collaboration with meiji seika pharma , offset by initial revenues recognized pursuant to these agreements . accounts payable and accrued expenses decreased by an aggregate of $ 3.1 million in 2010 compared to an aggregate decrease in accounts payable and accrued expenses of $ 1.6 million in 2009. the decrease in accounts payable and accrued expenses in 2010 was primarily due to payments made for external service costs related to our clinical trials , the timing and amount of which may fluctuate significantly from period to period . net cash provided by investing activities totaled $ 6.0 million in 2011 compared to net cash used in investing activities of $ 1.1 million in 2010 and net cash provided by investing activities of $ 9.4 million in 2009. net cash provided by or used in investing activities has fluctuated significantly from period to period primarily due to the timing of purchases and maturities of investment securities . the increase in net cash provided by investing activities in 2011 relative to the net cash used in investing activities in 2010 was primarily due to the maturities of investment securities exceeding purchases of investment securities . the increase in net cash used in investing activities in 2010 relative to net cash provided by investing activities in 2009 was primarily due to increased purchases of investment securities , net of maturities of investment securities . net cash provided by financing activities increased to $ 13.9 million in 2011 compared to $ 470,000 in 2010 and $ 1.2 million in 2009. the increase in net cash provided by financing activities during 2011 was primarily due to $ 13.9 million in net proceeds received from our january 2011 private equity financing . the decrease in net cash provided by financing activities in 2010 relative to 2009 was primarily attributable to reduced proceeds from the issuance of stock offset by decreased repayments of long-term debt . the following table summarizes our contractual obligations , including interest , at december 31 , 2011 ( in thousands ) : replace_table_token_5_th in april 2011 , we entered into a termination agreement related to the lease for our swedish research facility and ceased operations at this site . the lease was entered into in june 2005 and had a 10-year term . pursuant to this agreement , we made a one-time payment of $ 690,000 and issued 782,339 shares of our common stock to the landlord in settlement of all lease-related obligations . general and administrative expenses for the year ended december 31 , 2011 included a net charge of $ 1.1 million , which amount consisted of $ 1.7 million in lease termination charges offset by a $ 539,000 reduction in the cumulative translation adjustment balance related to the liquidation of substantially all assets of our swedish subsidiary . we have also entered into agreements with contract research organizations and other external service providers for services in connection with the development of our product candidates . we were contractually obligated for up to approximately $ 6.3 million of future services under these agreements as of december 31 , 2011. the nature of the work being conducted under our agreements with contract research organizations is such that , in most cases , the services may be stopped on short notice . in such event , we would not be liable

liquidity and capital resources since inception , we have funded our operations primarily through sales of our equity securities , payments received under our collaboration agreements , debt financings , and interest income . as of december 31 , 2011 , we had received $ 341.6 million in net proceeds from sales of our equity securities , including $ 6.9 million in debt we had retired through the issuance of our common stock , $ 112.5 million in payments from collaboration agreements , $ 22.4 million in debt financing , and $ 22.2 million in interest income . at december 31 , 2011 , we had $ 31.0 million in cash , cash equivalents and investment securities compared to $ 37.1 million at december 31 , 2010. we expect that our current cash , cash equivalents and investment securities , together with anticipated payments from our existing collaborations , will be sufficient to fund our operations at least into the second quarter of 2013. we will require significant additional financing in the future to fund our operations . our future capital requirements will depend on , and could increase significantly as a result of , many factors , including : progress in , and the costs of , our clinical trials , preclinical studies and other research and development programs ; the scope , prioritization and number of research and development programs ; 44 the ability of our collaborators and us to reach the milestones , or other events or developments , under our collaboration agreements ; the extent to which we are obligated to reimburse our collaborators or our collaborators


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```liquidity and capital resources since inception , we have funded our operations primarily through sales of our equity securities , payments received under our collaboration agreements , debt financings , and interest income . as of december 31 , 2011 , we had received $ 341.6 million in net proceeds from sales of our equity securities , including $ 6.9 million in debt we had retired through the issuance of our common stock , $ 112.5 million in payments from collaboration agreements , $ 22.4 million in debt financing , and $ 22.2 million in interest income . at december 31 , 2011 , we had $ 31.0 million in cash , cash equivalents and investment securities compared to $ 37.1 million at december 31 , 2010. we expect that our current cash , cash equivalents and investment securities , together with anticipated payments from our existing collaborations , will be sufficient to fund our operations at least into the second quarter of 2013. we will require significant additional financing in the future to fund our operations . our future capital requirements will depend on , and could increase significantly as a result of , many factors , including : progress in , and the costs of , our clinical trials , preclinical studies and other research and development programs ; the scope , prioritization and number of research and development programs ; 44 the ability of our collaborators and us to reach the milestones , or other events or developments , under our collaboration agreements ; the extent to which we are obligated to reimburse our collaborators or our collaborators
```    
 Suspicious Activity Report : this collaboration agreement is currently focused on the discovery of new therapeutics for ophthalmic indications and originally provided for a three-year research term , which has been extended by the parties through march 2013. our two other collaboration agreements with allergan involve the development of product candidates in the areas of 39 chronic pain and glaucoma . we are eligible to receive payments upon achievement of development and regulatory milestones , as well as royalties on future product sales , if any , under each of our three collaboration agreements with allergan . each of our agreements with allergan is subject to early termination upon specified events , including , in the case of one of our agreements , if we have a change in control . upon the conclusion of the research term under each agreement , allergan may terminate the agreement by notice . in march 2009 , we entered into a collaboration agreement with meiji seika pharma . under the agreement , we are eligible to receive up to $ 25 million in aggregate payments , consisting of $ 3 million in license fees and up to $ 22 million in payments upon achievement of development and regulatory milestones in the licensed asian territory . in addition , we are eligible to receive royalties on future product sales , if any , in the asian territory . meiji seika pharma also is responsible for the first $ 15 million of designated development expenses and we will share the remaining expenses through clinical proof-of-concept , subject to possible adjustment in the event we further license the program outside of the asian territory . as of december 31 , 2011 , we had received an aggregate of $ 4.3 million in payments from meiji seika pharma , consisting of license fees and reimbursed research and development expenses . our agreement with meiji seika pharma is subject to early termination upon specified events . in may 2009 , we entered into a collaboration agreement with biovail , pursuant to which we received a non-refundable $ 30 million upfront payment . under this collaboration , we also were eligible to receive potential development , regulatory and sales milestones as well as royalties on future net sales of pimavanserin . in october 2010 , we entered an agreement with biovail to regain all rights to pimavanserin and conclude our collaboration . in connection with this agreement , we recorded all remaining revenues related to our collaboration biovail , which totaled $ 34.7 million during the fourth quarter of 2010. we recognized aggregate revenues relating to the biovail collaboration of $ 39.5 million during the year ended december 31 , 2010. we have no future obligations to biovail . research and development expenses our research and development expenses have consisted primarily of fees paid to external service providers , salaries and related personnel expenses , facilities and equipment expenses , and other costs . we charge all research and development expenses to operations as incurred . our research and development activities are primarily focused on our most advanced product candidates , including pimavanserin . we currently are responsible for all costs incurred in the development of pimavanserin as well as for the costs associated with our other internal programs . pursuant to our collaboration , meiji seika pharma is responsible for the first $ 15 million of designated development expenses for the product candidate , am-831 , and we and meiji seika pharma will share remaining expenses through clinical proof-of-concept , subject to possible adjustment . as of december 31 , 2011 , approximately $ 2.8 million of the designated development expenses had been incurred . we expect to coordinate a significant portion of the planned external development services and , accordingly , we may incur the related development costs for these external services and receive reimbursement of meiji seika pharma 's portion of these costs pursuant to the agreement . meiji seika pharma is responsible for all costs associated with the development of am-831 in the asian territory . we are not responsible for , nor have we incurred , development expenses in our clinical programs for chronic pain and glaucoma , which we are pursuing in collaboration with allergan . 40 we use external service providers to manufacture our product candidates to be used in clinical trials and for the majority of the services performed in connection with the preclinical and clinical development of our product candidates . we have used our internal research and development resources , including our employees and discovery infrastructure , across several projects and many of our costs have not been attributable to a specific project but were directed to broadly applicable research activities . accordingly , we have not reported our internal research and development costs on a project basis . to the extent that external expenses are not attributable to a specific project , they are included in other external costs . the following table summarizes our research and development expenses for the years ended december 31 , 2011 , 2010 , and 2009 ( in thousands ) : replace_table_token_4_th at this time , due to the risks inherent in the clinical trial process and given the stage of development of our programs , we are unable to estimate with any certainty the costs we will incur for the continued development of our product candidates for potential commercialization . due to these same factors , we are unable to determine the anticipated completion dates for our current research and development programs . clinical development timelines , probability of success , and development costs vary widely . story_separator_special_tag the decrease in internal research and development costs was primarily attributable to $ 4.3 million in decreased salaries and related personnel costs , and decreases in laboratory supply , equipment , facility and other costs resulting from a restructuring and related workforce reductions implemented in october 2009. salaries and related personnel costs for the year ended december 31 , 2009 included a charge of $ 905,000 in connection with these workforce reductions . general and administrative expenses general and administrative expenses decreased to $ 6.5 million in 2010 , including $ 984,000 in stock-based compensation , from $ 10.3 million in 2009 , including $ 1.3 million in stock-based compensation . the decrease in general and administrative expenses was primarily due to $ 2.3 million in decreased salaries , related personnel costs and other costs resulting from our october 2009 restructuring and $ 1.6 million in decreased external service costs . story_separator_special_tag operating assets and liabilities , including changes in deferred revenue , accounts payable and accrued expenses , and a non-cash charge resulting from termination of our swedish facility lease during 2011. deferred revenue decreased by $ 57,000 in 2011 compared to a decrease of $ 25.3 million in 2010. the decrease in deferred revenue in 2010 was primarily attributable to the conclusion of our collaboration with biovail in october 2010 and the recognition of all remaining revenue under this collaboration . accounts payable and accrued expenses increased by an aggregate of $ 248,000 in 2011 compared to an aggregate decrease of $ 3.1 million in 2010. our accounts payable and accrued expenses fluctuated significantly during these years primarily due to the timing of payments made and expenses incurred for external service costs related to our clinical trials . 45 the decrease in net cash used in operating activities in 2010 relative to 2009 was primarily due to net income of $ 15.1 million in 2010 compared to a net loss of $ 45.1 million in 2009 , as well as changes in operating assets and liabilities , including changes in deferred revenue , and accounts payable and accrued expenses . deferred revenue decreased by $ 25.3 million in 2010 compared to an increase in deferred revenue of $ 28.2 million in 2009. the decrease in deferred revenue in 2010 was primarily attributable to the recognition of $ 25.9 million in deferred revenue in connection with the conclusion of our collaboration with biovail in october 2010. the increase in deferred revenue in 2009 was primarily attributable to the $ 30 million non-refundable upfront payment received pursuant to our collaboration with biovail as well as initial licensing fees received from our collaboration with meiji seika pharma , offset by initial revenues recognized pursuant to these agreements . accounts payable and accrued expenses decreased by an aggregate of $ 3.1 million in 2010 compared to an aggregate decrease in accounts payable and accrued expenses of $ 1.6 million in 2009. the decrease in accounts payable and accrued expenses in 2010 was primarily due to payments made for external service costs related to our clinical trials , the timing and amount of which may fluctuate significantly from period to period . net cash provided by investing activities totaled $ 6.0 million in 2011 compared to net cash used in investing activities of $ 1.1 million in 2010 and net cash provided by investing activities of $ 9.4 million in 2009. net cash provided by or used in investing activities has fluctuated significantly from period to period primarily due to the timing of purchases and maturities of investment securities . the increase in net cash provided by investing activities in 2011 relative to the net cash used in investing activities in 2010 was primarily due to the maturities of investment securities exceeding purchases of investment securities . the increase in net cash used in investing activities in 2010 relative to net cash provided by investing activities in 2009 was primarily due to increased purchases of investment securities , net of maturities of investment securities . net cash provided by financing activities increased to $ 13.9 million in 2011 compared to $ 470,000 in 2010 and $ 1.2 million in 2009. the increase in net cash provided by financing activities during 2011 was primarily due to $ 13.9 million in net proceeds received from our january 2011 private equity financing . the decrease in net cash provided by financing activities in 2010 relative to 2009 was primarily attributable to reduced proceeds from the issuance of stock offset by decreased repayments of long-term debt . the following table summarizes our contractual obligations , including interest , at december 31 , 2011 ( in thousands ) : replace_table_token_5_th in april 2011 , we entered into a termination agreement related to the lease for our swedish research facility and ceased operations at this site . the lease was entered into in june 2005 and had a 10-year term . pursuant to this agreement , we made a one-time payment of $ 690,000 and issued 782,339 shares of our common stock to the landlord in settlement of all lease-related obligations . general and administrative expenses for the year ended december 31 , 2011 included a net charge of $ 1.1 million , which amount consisted of $ 1.7 million in lease termination charges offset by a $ 539,000 reduction in the cumulative translation adjustment balance related to the liquidation of substantially all assets of our swedish subsidiary . we have also entered into agreements with contract research organizations and other external service providers for services in connection with the development of our product candidates . we were contractually obligated for up to approximately $ 6.3 million of future services under these agreements as of december 31 , 2011. the nature of the work being conducted under our agreements with contract research organizations is such that , in most cases , the services may be stopped on short notice . in such event , we would not be liable

